top of page
IMG_5960_edited.jpg

Scientific interests

The Corti Lab is focused on an urgent human need related to neurological diseases.

Neurodegenerative diseases are highly disabling and fatal disorders, often without a cure, that place a huge burden on patients and their families and have a significant impact on society. There is urgent need to find effective treatment for these conditions.

Our research is focused on cellular (stem cells) and molecular therapies (gene therapies, antisense oligonucleotides) for neurodegenerative diseases, in particular motor neuron diseases (Amyotrophic Lateral Sclerosis, ALS, Spinal Muscular Atrophy, SMA, Spinal Muscular Atrophy with Respiratory Distress type 1, SMARD1), neuropathies (CMT2A) and neuromuscular diseases.

We  established patient-specific  2D and 3D models (iPSC-derived organoids patterned into brain/spinal cord) to study disease pathogenesis and develop novel therapeutic strategies for neurological diseases.

Our group creates synergistic  programs for target discovery and functional analysis in an intellectual, collegial and stimulating environment.

 

 University of Milan and Foundation IRCCS Ca' Granda offer an unparalleled location for this initiative because they currently houses, in close proximity, world-class research and clinical groups. These include scientists engaged in the study of neuronal function, relevant aspects of stem cell biology and in vitro and in vivo models of human diseases. These scientists work with internationally renowned clinicians experienced in clinical trials for neurological diseases, committed to apply into their programs the latest findings from basic research and able to provide advice about the feasibility of therapeutic approaches for humans.

​​

Areas of investigation

Molecular therapies for neurodegenerative diseases

Neural stem cell transplantation as therapeutic approach

Reprogramming neuronal identity in vitro and in vivo

Modeling human neurological disease in vitro

 

Tools: stem cells, iPSC, organoids, gene therapy, ASO

Target diseases: SMA, ALS, CMT2A, motor neuron diseases, rare neurological diseases

bottom of page